Lilly’s $149/Month Foundayo Approval Pushes Down Novo Nordisk ADRs
Eli Lilly's Foundayo weight-loss pill won FDA approval at $149 per month, with U.S. shipments starting April 6, sending Novo Nordisk ADRs down as much as 2.6%. Novo’s oral semaglutide pill drove 13.6% weight loss over 64 weeks but faces pricing and dosing constraints as Lilly challenges its lead.
1. FDA Approval of Foundayo
The FDA granted approval to Lilly’s Foundayo oral weight-loss pill under an expedited review program, recognizing it as a promising treatment to help patients shed pounds or maintain prior weight loss.
2. Shipment and Pricing
Foundayo will be available through LillyDirect starting April 6, priced at $149 per month for cash-paying patients, with strategic production of billions of doses to support rapid market entry.
3. Impact on Novo Nordisk ADRs
Following the approval announcement, Novo Nordisk American depositary receipts fell by up to 2.6% before rebounding, reflecting investor concern over increased competition in the obesity drug market.
4. Comparative Efficacy and Constraints
In trials, Novo’s pill delivered a 13.6% average weight reduction over 64 weeks but imposes strict dosing rules, whereas Foundayo’s more flexible regimen and lower price may erode Novo’s market lead.